Newsletter Tool

PM Tracker

Today’s Big News

Jun 12, 2025

RFK Jr. names 8 new members to CDC's vaccine advisory committee after purging entire panel

Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum

ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%

Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi

Medtronic adopts familiar name for its planned diabetes spinout: MiniMed

UCB touts plan for 'major' US investment to boost biologics capacity

Featured

RFK Jr. names 8 new members to CDC's vaccine advisory committee after purging entire panel

By Heather Landi

HHS Secretary Robert F. Kennedy Jr. named eight new members to serve on the Centers for Disease Control and Prevention's vaccine advisory panel just two days after he removed all 17 sitting members of the key advisory committee.

Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum

By Angus Liu

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and "moderating" new-to-brand prescription growth. But the company's top executives don't see things that way.

ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%

By Gabrielle Masson

After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce.

Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi

By Andrea Park

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion.

Medtronic adopts familiar name for its planned diabetes spinout: MiniMed

By Conor Hale

Medtronic has landed on a new brand for the planned spinout of its diabetes division, and it didn’t have to look very far.

UCB touts plan for 'major' US investment to boost biologics capacity

By Eric Sagonowsky

Belgium's UCB is adding its name to the mix of drugmakers planning to grow their manufacturing footprints in the U.S.

BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal

By James Waldron

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.

AstraZeneca takes $181M hit in Syntimmune shareholder lawsuit on top of previous $130M award

By Kevin Dunleavy

For the second time in nine months, a Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million judgment issued in September of last year.

Exoskeleton maker Wandercraft raises $75M alongside Renault partnership

By Conor Hale

Wandercraft's series D will help boost clinical adoption of its suits for rehabilitation and mobility as well as support its industrial programs.

Havas creates health ad market for reaching underserved patients

By Nick Paul Taylor

Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by geographic or socioeconomic barriers.

EHA: GSK adds fuel to Blenrep's comeback case ahead of potential US return

By Zoey Becker

GSK's multiple myeloma antibody drug conjugate Blenrep is up for an FDA decision in July. If approved, the drug would complete a return to the U.S. market after it was withdrawn following a failed confirmatory study in 2022.

Fierce podcasts

Don’t miss an episode

Inside the evolving playbook for employee wellbeing

This week on "Podnosis," we explore how employers are rethinking their approach to employee wellbeing—integrating mental, physical and financial health strategies to better reach the people who need them most.